Guzzetti Chiara, Ibba Anastasia, Casula Letizia, Pilia Sabrina, Casano Simona, Loche Sandro
SSD Endocrinologia Pediatrica e Centro Screening Neonatale, Ospedale Pediatrico Microcitemico "A. Cao", Azienda Ospedaliera Brotzu, Cagliari, Italy.
Front Endocrinol (Lausanne). 2019 Aug 27;10:591. doi: 10.3389/fendo.2019.00591. eCollection 2019.
To evaluate the effect of gender and puberty on cardiovascular risk factors (CVRF) in obese children and adolescents. One thousand four hundred and nine obese patients [age 9.7 (2.2-17.9) y; 646 Male] were studied. Subjects were stratified according to Tanner pubertal staging and age into prepubertal ≤ and >6 ys (G1 and G2), pubertal stage 2-3 (G3), and pubertal stage 4-5 (G4). Waist circumference (WC), systolic and diastolic blood pressure (SP, DP), fasting plasma glucose, insulin, post Oral Glucose Tolerance Test glucose and insulin, and lipids were evaluated. Insulin resistance was evaluated by HOMA index. Patients with no CVRF were considered metabolically healthy (MHO). The percentage of MHO patients was 59.8% in G1 while was consistently around 30% in the other groups. WC was more frequently abnormal in G2 males. Pubertal progression was associated with a decrease in WC abnormalities. SP was more frequently abnormal in G4 males and pubertal progression was associated with higher prevalence of abnormal SP in males. Pubertal progression was associated with an increase in hypertension rate in both sexes. HOMA was more frequently abnormal in G2 and G3 females. HDL, LDL, and TG were more frequently abnormal in G2 females. Dyslipidemia rate was higher in G2 females. Pubertal progression was associated with higher prevalence of abnormal HDL in males. Sex and pubertal status influence the frequency of abnormalities of CVRF in obese children and adolescents. CVRF are already present in prepubertal age. Identifying patients with higher risk of metabolic complications is important to design targeted and effective prevention strategies.
评估性别和青春期对肥胖儿童及青少年心血管危险因素(CVRF)的影响。对1409名肥胖患者[年龄9.7(2.2 - 17.9)岁;646名男性]进行了研究。根据坦纳青春期分期和年龄将受试者分为青春期前≤6岁和>6岁(G1和G2)、青春期2 - 3期(G3)以及青春期4 - 5期(G4)。评估了腰围(WC)、收缩压和舒张压(SP、DP)、空腹血糖、胰岛素、口服葡萄糖耐量试验后血糖和胰岛素以及血脂。通过稳态模型评估法(HOMA)指数评估胰岛素抵抗。无CVRF的患者被视为代谢健康(MHO)。MHO患者在G1组中的比例为59.8%,而在其他组中一直约为30%。WC在G2组男性中更常出现异常。青春期进展与WC异常的减少相关。SP在G4组男性中更常出现异常,且青春期进展与男性SP异常的较高患病率相关。青春期进展与男女高血压发生率的增加相关。HOMA在G2和G3组女性中更常出现异常。HDL、LDL和TG在G2组女性中更常出现异常。G2组女性的血脂异常率更高。青春期进展与男性HDL异常的较高患病率相关。性别和青春期状态影响肥胖儿童及青少年CVRF异常的频率。CVRF在青春期前就已存在。识别代谢并发症风险较高的患者对于设计有针对性且有效的预防策略很重要。